Plasma Fractionation Market

Plasma Fractionation Market by Product [IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor], Application (Immunology, Hematology, Critical Care, Rheumatology) End User (Hospital, Clinic, Academic Institute)-Global Forecast to 2024

Report Code: PH 4477 Mar, 2019, by marketsandmarkets.com

[300 Pages Report] The plasma fractionation market is projected to reach USD 34.9 billion by 2024 from USD 25.4 billion in 2019, at a CAGR of 6.6% during the forecast period. The plasma fractionation market is largely driven by the growing use of immunoglobulins in various therapeutic areas, increase in plasma collection (and the number of plasma collection centers), and the increasing use of alpha-1-antitrypsin. However, the high cost of plasma products, limited reimbursements, and the emergence of recombinant alternatives are expected to restrain the growth of this market during the forecast period.

This report segments the plasma fractionation market by product, application, end user, and region.

Plasma Fractionation Market

The subcutaneous immunoglobulin products segment is expected to grow at the highest CAGR during the forecast period.

Based on type, the subcutaneous immunoglobulin products segment is expected to grow at the highest CAGR in the immunoglobulin market during the forecast period. SCIg has several advantages over IVIg—for one, it is the best alternative for patients with limited vascular access who cannot tolerate adverse effects associated with IVIg. Slow administration and absorption of SCIg reduce the rapid variation in serum Ig levels, which further reduces adverse drug reactions. These advantages are expected to drive the growth in this product segment.

The Von Willebrand factor segment is expected to grow at the highest CAGR during the forecast period.

Based on type, the Von Willebrand factor segment is expected to show the fastest growth in the coagulation factor concentrates market during the forecast period. The growth of this market can be primarily attributed to the increasing prevalence and diagnosis of the Von Willebrand disease and hemophilia across the world.

North America dominated the plasma fractionation market in 2018; this trend is expected to continue during the forecast period.

Geographically, the plasma fractionation market has been studied for North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to dominate the plasma fractionation market during the forecast period. Growth in North America is primarily driven by the growing use of immunoglobulin in various therapeutic areas, growing geriatric population, and the increasing prevalence of respiratory diseases and AATD. Furthermore, several innovations in manufacturing processes (e.g. improvement of yield), product developments (e.g. such as subcutaneous IG, IVIg 10% concentration, and IVIg liquid presentation), presence of advanced virus removal technologies (such as nanofiltration), and the development of newer plasma products such as ceruloplasmin and IgA are also supporting the growth of the plasma fractionation market in these regions.

Plasma Fractionation Market

Key Market Players

Major players in the global plasma fractionation market include CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China). Geographic expansions and collaborations are the key strategies undertaken by these companies to maintain their positions in the market.

Recent Developments

  • In January 2019, Takeda Pharmaceutical Company Limited (Japan), a global biopharmaceutical company acquired Shire, increasing its geographic footprint and global customer base.
  • In September 2018, Grifols launched GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles postexposure prophylaxis, and Prolastin-C Liquid [alpha-1 proteinase inhibitor, liquid] for the treatment of alpha-1 antitrypsin deficiency
  • In September 2018, Octapharma invested USD 25 million (Euro 21 million) in a new multi-function facility in Springe, Germany, that will have a new production line for human normal immunoglobulin panzyga, alongside with human albumi and albunorm.
  • In August 2018, Grifols acquired Biotest US Corporation, a subsidiary of Biotest (Germany), to expand its plasma collection network with the addition of 24 Biotest centers in the US
  • In February 2018, Guizhou Taibang Biological Products Co. Ltd., a wholly-owned subsidiary of China Biologic Products Organization, received approval from the Hainan Provincial Health and Family Planning Commission to build a new plasma collection station in Hainan Province.

Key Questions Addressed in the Report

  • Who are the top 10 players operating in the plasma fractionation market?
  • What are the driving factors, restraints, opportunities, and challenges in the plasma fractionation market?
  • What are the industry trends and current scenario of the plasma fractionation market?
  • What are the growth trends in the plasma fractionation market at the segmental and overall market levels?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Table of Contents

1 Introduction (Page No. - 24)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Scope of the Study
           1.3.1 Markets Covered
           1.3.2 Years Considered for the Study
    1.4 Currency
    1.5 Stakeholders

2 Research Methodology (Page No. - 27)
    2.1 Research Approach
           2.1.1 Secondary Sources
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Sources
                    2.1.2.1 Primary Sources
                    2.1.2.2 Key Data From Primary Sources
                    2.1.2.3 Key Industry Insights
    2.2 Market Size Estimation
           2.2.1 Bottom-Up Approach
           2.2.2 Top-Down Approach
    2.3 Market Breakdown and Data Triangulation
    2.4 Market Share Estimation
    2.5 Assumptions for the Study
    2.6 Limitations

3 Executive Summary (Page No. - 37)

4 Premium Insights (Page No. - 41)
    4.1 Plasma Fractionation Market Overview
    4.2 Geographical Snapshot of the Plasma Fractionation Market
    4.3 Plasma Fractionation Market: Regional Mix
    4.4 Plasma Fractionation Market, Developing Countries vs Developed Countries

5 Market Overview (Page No. - 45)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Market Drivers
                    5.2.1.1 Growing Use of Immunoglobulins in Various Therapeutic Areas
                    5.2.1.2 Rising Geriatric Population Across the Globe
                    5.2.1.3 Growing Prevalence of Respiratory Diseases and Aatd Driving the Uptake of Alpha-1-Antitrypsin
                    5.2.1.4 Increase in Plasma Collection
           5.2.2 Market Restraints
                    5.2.2.1 High Cost and Limited Reimbursement
                    5.2.2.2 Emergence of Recombinant Alternatives
           5.2.3 Market Opportunities
                    5.2.3.1 Rising Prevalence of Bleeding Disorders
           5.2.4 Market Challenges
                    5.2.4.1 Stringent Government Regulations

6 Industry Insights (Page No. - 54)
    6.1 Introduction
    6.2 Key Industry Trends
           6.2.1 Focus on Increasing Fractionation Capacities
           6.2.2 New Indications for Plasma Products
           6.2.3 Rising Adoption of SCIg
           6.2.4 Increasing Number of Fractionator-Owned Plasma Collection Centers
           6.2.5 Growing Plasma Products Market in China
           6.2.6 Increasing Focus of Plasma Fractionators Towards Manufacturing and Developing Recombinant Factors
    6.3 Porter’s Five Forces
           6.3.1 Threat of New Entrants
           6.3.2 Threat of Substitutes
           6.3.3 Bargaining Power of Suppliers
           6.3.4 Bargaining Power of Buyers
           6.3.5 Intensity of Competitive Rivalry
    6.4 Vendor Benchmarking
           6.4.1 Product Portfolio Analysis: Plasma Fractionation Market
           6.4.2 No. of Plasma Collection Centers and Fractionation Capacities, By Key Player
           6.4.3 Business Presence of Key Players in the Value Chain
    6.5 Pricing Analysis

7 Plasma Fractionation Market, By Product (Page No. - 69)
    7.1 Introduction
    7.2 Immunoglobulins
           7.2.1 Intravenous Immunoglobulins
                    7.2.1.1 IVIg Holds the Largest Share of the Immunoglobulins Market
           7.2.2 Subcutaneous Immunoglobulins
                    7.2.2.1 Benefit of Self-Administration and Lower Incidence of Non-Serious Systemic Adverse Reactions Will Drive the Growth of the SCIg Market
           7.2.3 Other Immunoglobulins
    7.3 Coagulation Factor Concentrates
           7.3.1 Factor VIII
                    7.3.1.1 Factor VIII Holds the Largest Share of the Coagulation Factor Concentrates Market
           7.3.2 Factor IX
                    7.3.2.1 Growth in the Aging Population and the Rise in the Number of Hemophilic Patients is Expected to Drive the Growth in This Market
           7.3.3 Von Willebrand Factor
                    7.3.3.1 Market Growth is Primarily Driven By the Increasing Prevalence and Diagnosis of Von Willebrand Disease and Hemophilia
           7.3.4 Prothrombin Complex Concentrate
                    7.3.4.1 Advantages of Pcc Over Fresh Frozen Plasma Will Support Market Growth in This Segment
           7.3.5 Fibrinogen Concentrates
                    7.3.5.1 Safety Profile, Accuracy, and Speed of Administration Have Supported the Growth of the Fibrinogen Concentrates Market
           7.3.6 Factor XIII
                    7.3.6.1 Applications in Treating Rare Bleeding Disorders Will Contribute to the Demand for Factor XIII
    7.4 Albumin
           7.4.1 Wide Demand for Albumin as an Antioxidant and Volume Expander Will Drive Market Growth
    7.5 Protease Inhibitors
           7.5.1 Increasing Global Disease Burden Will Drive Demand for Protease Inhibitors
    7.6 Other Products

8 Plasma Fractionation Market, By Application (Page No. - 104)
    8.1 Introduction
    8.2 Neurology
           8.2.1 Rising Prevalence of Major Age-Related Neurological Disorders to Drive This Market
    8.3 Immunology
           8.3.1 Increasing Prevalence of Immunodeficiency Disorders Among Children and Adults to Drive the Growth of This Market
    8.4 Hematology
           8.4.1 Growth in the Number of Hemophilia Patients to Drive the Demand for Coagulation Factor Concentrates and Immunoglobulins
    8.5 Critical Care
           8.5.1 Increasing Off-Label Use of Albumin and Rising Use of Anticoagulants to Drive the Demand for Plasma-Derived Critical Care Products
    8.6 Pulmonology
           8.6.1 Rising Prevalence of Alpha-1 Antitrypsin Deficiency and Copd to Drive the Plasma Fractionation Market for Pulmonology
    8.7 Hemato-Oncology
           8.7.1 Rising Number of Blood Cancer Patients to Drive the Demand for Plasma-Derived Products in Hemato-Oncology
    8.8 Rheumatology
           8.8.1 Increasing Prevalence of Rheumatic Conditions to Drive the Plasma Fractionation Market for Rheumatology
    8.9 Other Applications

9 Plasma Fractionation Market, By End User (Page No. - 124)
    9.1 Introduction
    9.2 Hospitals & Clinics
           9.2.1 Improving Healthcare Infrastructure and Growth in the Number of Hospitals & Clinics—Key Factors Driving Growth
    9.3 Clinical Research Laboratories
           9.3.1 Increasing Number of Clinical Studies on New Therapeutic Indications for Plasma-Derived Products to Drive the Market for Clinical Research Laboratories
    9.4 Academic Institutes
           9.4.1 Increasing Basic Medical Research Activities and Growing Demand for New Drug Molecules to Drive the Demand for Plasma Products in Academic Institutes

10 Plasma Fractionation Market, By Region (Page No. - 132)
     10.1 Introduction
     10.2 North America
             10.2.1 US
                        10.2.1.1 The US Dominates the Global Plasma Fractionation Market
             10.2.2 Canada
                        10.2.2.1 Canada is One of the World's Highest Per Capita Users of IVIg
     10.3 Europe
             10.3.1 Germany
                        10.3.1.1 Germany has the Highest Plasma Fractionation Capacity in Europe
             10.3.2 France
                        10.3.2.1 High Prevalence of Bleeding Disorders to Drive the Market for Plasma Fractionation in France
             10.3.3 Italy
                        10.3.3.1 Growth in the Country’s Geriatric Population to Drive the Market for Plasma Fractionation
             10.3.4 Spain
                        10.3.4.1 Growing Demand for Plasma Products for the Treatment of Chronic Diseases in the Elderly is the Key Factor Driving Market Growth
             10.3.5 UK
                        10.3.5.1 Increasing Incidence of Hemophilia and the Growing Consumption of Coagulation Factors to Drive Market Growth in the UK
             10.3.6 Rest of Europe
     10.4 Asia Pacific
             10.4.1 China
                        10.4.1.1 Significant Growth in the Incidence of Diseases Such as Hypoalbuminemia, Liver Cancer, and Hepatitis B are Driving the Growth of Plasma-Derived Products Market in China
             10.4.2 Japan
                        10.4.2.1 The Rising Geriatric Population is Expected to Increase the Prevalence of Neurological Disorders and Hematological Diseases in Japan in the Coming Years
             10.4.3 Australia
                        10.4.3.1 High Production of Plasma Products and the Growing Demand for Plasma Products for the Treatment of Chronic Disease to Drive Market Growth
             10.4.4 India
                        10.4.4.1 Growing Healthcare Awareness, Availability of Better Diagnostic Tools, and the Rising Geriatric Population to Drive Market Growth
             10.4.5 Vietnam
                        10.4.5.1 Growing Pool of Patients Suffering From Copd, Pid, and Bleeding Disorders to Drive Market Growth
             10.4.6 Indonesia
                        10.4.6.1 Growing Government Initiatives to Drive Market Growth
             10.4.7 Malaysia
                        10.4.7.1 Growing Healthcare Awareness, Increasing Prevalence of Bleeding Disorders, and the Rising Geriatric Population are the Major Factors Driving Market Growth
             10.4.8 Rest of Asia Pacific
     10.5 Latin America
             10.5.1 Implementation of Government Initiatives to Promote Healthcare Services, Rising Geriatric Population, and Increasing Incidence of Bleeding Disorders to Drive Market Growth in Latin America
     10.6 Middle East & Africa
             10.6.1 Turkey
                        10.6.1.1 Turkey Dominated the Plasma Fractionation Market in the Middle East and Africa
             10.6.2 Saudi Arabia
                        10.6.2.1 Rising Use of Immunoglobulins in Neurology and Immunology and the Strengthening of Healthcare Infrastructure to Drive Market Growth
             10.6.3 Egypt
                        10.6.3.1 Growing Research on Plasma and Plasma Derivatives and the Increasing Adoption of Plasma Products to Drive Market Growth
             10.6.4 UAE
                        10.6.4.1 Increasing Incidence of Bleeding Disorders and Growing Government Initiatives for Healthcare Infrastructure Development to Drive Market Growth
             10.6.5 Rest of Middle East and Africa

11 Competitive Landscape (Page No. - 236)
     11.1 Overview
     11.2 Market Share Analysis
             11.2.1 Market Share Analysis, By Product,2018
                        11.2.1.1 Immunoglobulin Market, By Key Players
                                     11.2.1.1.1 IVIg Market, By Key Players
                        11.2.1.2 Coagulation Factor Market, By Key Players
                                     11.2.1.2.1 Factor VIII Market, By Key Players
                        11.2.1.3 Albumin Market, By Key Players
             11.2.2 Market Share Analysis, By Region,2018
                        11.2.2.1 North America Plasma Fractionation Market, By Key Players
                                     11.2.2.1.1 US Plasma Fractionation Market, By Key Players
                        11.2.2.2 Europe Plasma Fractionation Market, By Key Players
     11.3 Competitive Leadership Mapping
             11.3.1 Visionary Leaders
             11.3.2 Innovators
             11.3.3 Dynamic Differentiators
             11.3.4 Emerging Companies
     11.4 Competitive Scenario and Trends
             11.4.1 Product Launches/Approvals
             11.4.2 Expansions
             11.4.3 Acquisitions
             11.4.4 Agreements, Collaborations, Joint Ventures, and Partnerships

12 Company Profiles (Page No. - 250)
     12.1 CSL
             12.1.1 Business Overview
             12.1.2 Products Offered
             12.1.3 Recent Developments
             12.1.4 SWOT Analysis
             12.1.5 MnM View
     12.2 Grifols
             12.2.1 Business Overview
             12.2.2 Products Offered
             12.2.3 Recent Developments
             12.2.4 SWOT Analysis
             12.2.5 MnM View
     12.3 Shire
             12.3.1 Business Overview
             12.3.2 Products Offered
             12.3.3 Recent Developments
             12.3.4 SWOT Analysis
             12.3.5 MnM View
     12.4 Octapharma
             12.4.1 Business Overview
             12.4.2 Products Offered
             12.4.3 Recent Developments
             12.4.4 SWOT Analysis
             12.4.5 MnM Analysis
     12.5 Kedrion
             12.5.1 Business Overview
             12.5.2 Products Offered
             12.5.3 Recent Developments
             12.5.4 SWOT Analysis
             12.5.5 MnM View
     12.6 LFB
             12.6.1 Business Overview
             12.6.2 Products Offered
             12.6.3 Recent Developments
             12.6.4 MnM View
     12.7 Biotest
             12.7.1 Business Overview
             12.7.2 Products Offered
             12.7.3 Recent Developments
             12.7.4 MnM View
     12.8 Sanquin
             12.8.1 Business Overview
             12.8.2 Products Offered
             12.8.3 MnM View
     12.9 China Biologic Products
             12.9.1 Business Overview
             12.9.2 Products Offered
             12.9.3 Recent Developments
             12.9.4 MnM View
     12.10 Bio Products Laboratory (BPL)
             12.10.1 Business Overview
             12.10.2 Products Offered
             12.10.3 Recent Developments
             12.10.4 MnM View
     12.11 Japan Blood Products Organization
             12.11.1 Business Overview
             12.11.2 Products Offered
             12.11.3 MnM View
     12.12 GC Pharma (Green Cross Corporation)
             12.12.1 Business Overview
             12.12.2 Products Offered
             12.12.3 Recent Developments
             12.12.4 MnM View
     12.13 Shanghai RAAS Blood Products
             12.13.1 Business Overview
             12.13.2 Products Offered
             12.13.3 Recent Developments
             12.13.4 MnM View

13 Appendix (Page No. - 291)
     13.1 Insights of Industry Experts
     13.2 Discussion Guide
     13.3 Available Customization
     13.4 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.5 Related Report
     13.6 Author Details


List of Tables (265 Tables)

Table 1 Plasma Fractionation Market: Impact Analysis
Table 2 On-Label and Off-Label Indications of IVIG
Table 3 Number of Clinical Studies on Immunoglobulins, By Region, 2017
Table 4 Number of Patients Treated for Top 10 Target Conditions in the UK (2015-16)
Table 5 Increase in Geriatric Population From 2000 to 2050 Across the Globe
Table 6 Number of Plasma Collection Centers, By Company, 2018
Table 7 Number of Hemophilia Patients in Developed and Emerging Countries, 2016 vs 2017
Table 8 Fractionation Capacity Expansions By Major Players
Table 9 Per Capita Consumption of IVIG and Albumin, By Country (2014)
Table 10 China: Top Players in the Plasma Fractionation Market, 2018
Table 11 Major Local Players in China
Table 12 Regional Impact Analysis of Recombinant Factors on Plasma-Derived Products
Table 13 Average Selling Price of Plasma Fractionation Products, By Player (2018)
Table 14 Average Selling Price of Plasma Fractionation Products, By Region (2018)
Table 15 Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 16 IVIG vs SCIG Therapy
Table 17 Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 18 Immunoglobulins Market, By Country, 2017–2024 (USD Million)
Table 19 Intravenous Immunoglobulins Offered By Key Market Players
Table 20 Intravenous Immunoglobulins Market, By Country, 2017–2024 (USD Million)
Table 21 Intravenous Immunoglobulins Market, By Region, 2017–2024 (Metric Tons)
Table 22 Subcutaneous Immunoglobulins Offered By Key Market Players
Table 23 Subcutaneous Immunoglobulins Market, By Country, 2017–2024 (USD Million)
Table 24 Subcutaneous Immunoglobulins Market, By Region, 2017–2024 (Metric Tons)
Table 25 Other Immunoglobulins Offered By Key Market Players
Table 26 Other Immunoglobulins Market, By Country, 2017–2024 (USD Million)
Table 27 Other Immunoglobulins Market, By Region, 2017–2024 (Million International Units)
Table 28 Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 29 Coagulation Factor Concentrates Market, By Country, 2017–2024 (USD Million)
Table 30 Factor VIII Offered By Key Market Players
Table 31 Factor VIII Market, By Country, 2017–2024 (USD Million)
Table 32 Factor VIII Market, By Region, 2017–2024 (Million International Units)
Table 33 Factor IX Offered By Key Market Players
Table 34 Factor IX Market, By Country, 2017–2024 (USD Million)
Table 35 Von Willebrand Factor Offered By Key Market Players
Table 36 Von Willebrand Factor Market, By Country, 2017–2024 (USD Million)
Table 37 Prothrombin Complex Concentrates Offered By Key Market Players
Table 38 Prothrombin Complex Concentrates Market, By Country, 2017–2024 (USD Million)
Table 39 Fibrinogen Concentrates Offered By Key Market Players
Table 40 Fibrinogen Concentrates Market, By Country, 2017–2024 (USD Million)
Table 41 Factor XIII Offered By Key Market Players
Table 42 Factor XIII Market, By Country, 2017–2024 (USD Million)
Table 43 Albumin Offered By Key Market Players
Table 44 Albumin Market, By Country, 2017–2024 (USD Million)
Table 45 Global Albumin Market, By Region, 2017–2024 (Metric Tons)
Table 46 Protease Inhibitors Offered By Key Market Players
Table 47 Protease Inhibitors Market, By Country, 2017–2024 (USD Million)
Table 48 Other Products Market, By Country, 2017–2024 (USD Million)
Table 49 Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 50 Number of Dalys for Neurological Disorders and the Percentage of Dalys Projected for 2005, 2015, and 2030
Table 51 Plasma-Derived Products and Their Applications in Neurology
Table 52 Plasma Fractionation Market for Neurology, By Country, 2017–2024 (USD Million)
Table 53 List of Fda-Approved Indications for Immunoglobulins in Immunology
Table 54 Primary Immunodeficiency Disease, By Type
Table 55 Prevalence of Primary Immunodeficiency Disease, By Region, 2013 vs 2015
Table 56 Plasma-Derived Products and Their Applications in Immunology
Table 57 Plasma Fractionation Market for Immunology, By Country, 2017–2024 (USD Million)
Table 58 Number of Hemophilia Patients (2012–2017)
Table 59 Plasma-Derived Products and Their Applications in Hematology
Table 60 Plasma Fractionation Market for Hematology, By Country, 2017–2024 (USD Million)
Table 61 Plasma-Derived Products and Their Applications in Critical Care
Table 62 Plasma Fractionation Market for Critical Care, By Country, 2017–2024 (USD Million)
Table 63 Plasma-Derived Products and Their Applications in Pulmonology
Table 64 Plasma Fractionation Market for Pulmonology, By Country, 2017–2024 (USD Million)
Table 65 Incidence of Leukemia, Multiple Myeloma, and Hodgkin Lymphoma, By Region, 2012 vs 2015 vs 2018
Table 66 Plasma-Derived Products and Their Applications in Hemato-Oncology
Table 67 Plasma Fractionation Market for Hemato-Oncology, By Country, 2017–2024 (USD Million)
Table 68 Plasma Fractionation Market for Rheumatology, By Country, 2017–2024 (USD Million)
Table 69 Plasma-Derived Products for Other Applications
Table 70 Plasma Fractionation Market for Other Applications, By Country, 2017–2024 (USD Million)
Table 71 Plasma Fractionation Market, By End USer, 2017–2024 (USD Million)
Table 72 Plasma Fractionation Market for Hospitals & Clinics, By Country, 2017–2024 (USD Million)
Table 73 Clinical Studies on Albumin & Immunoglobulin (2017)
Table 74 Plasma Fractionation Market for Clinical Research Laboratories, By Country, 2017–2024 (USD Million)
Table 75 Plasma Fractionation Market for Academic Institutes, By Country, 2017–2024 (USD Million)
Table 76 Regional Distribution of Plasma Fractionation Plants and Plasma Throughput, By Region, 2014
Table 77 Plasma Fractionation Market, By Region, 2017–2024 (USD Million)
Table 78 North America: Hemophilia Patients, 2013 vs 2017
Table 79 Transfer of Plasma From US to Other Regions, 2014
Table 80 North America: Plasma Fractionation Market, By Country, 2017–2024 (USD Million)
Table 81 North America: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 82 North America: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 83 North America: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 84 North America: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 85 North America: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 86 US: Key Macroindicators for the Plasma Fractionation Market
Table 87 US: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 88 US: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 89 US: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 90 US: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 91 US: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 92 Canada: Key Macroindicators for the Plasma Fractionation Market
Table 93 Canada: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 94 Canada: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 95 Canada: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 96 Canada: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 97 Canada: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 98 Europe: Plasma Collection, 2007–2016
Table 99 Plasma Fractionation Plants in Europe (2017)
Table 100 Europe: Plasma Fractionation Market, By Country, 2017–2024 (USD Million)
Table 101 Europe: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 102 Europe: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 103 Europe: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 104 Europe: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 105 Europe: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 106 Germany: Key Macroindicators for the Plasma Fractionation Market
Table 107 Germany: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 108 Germany: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 109 Germany: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 110 Germany: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 111 Germany: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 112 Number of People With Bleeding Disorders in France, 2012–2017
Table 113 France: Key Macroindicators for the Plasma Fractionation Market
Table 114 France: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 115 France: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 116 France: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 117 France: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 118 France: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 119 Italy: Number of Blood Donations, 2011 vs 2013
Table 120 Production of Plasma Products in Italy (2013, 2018-E, & 2023-E)
Table 121 Italy: Key Macroindicators for the Plasma Fractionation Market
Table 122 Italy: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 123 Italy: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 124 Italy: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 125 Italy: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 126 Italy: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 127 Spain: Key Macroindicators for the Plasms Fractionation Market
Table 128 Spain: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 129 Spain: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 130 Spain: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 131 Spain: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 132 Spain: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 133 Usage of Immunoglobulins
Table 134 Estimated Number of Hemophilia A and Hemophilia B Patients in the Uk, 2012–2016
Table 135 Volume of Immunoglobulins Used for the Top 5 Diagnoses (2016)
Table 136 UK: Key Macroindicators for the Plasma Fractionation Market
Table 137 UK: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 138 UK: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 139 UK: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 140 UK: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 141 UK: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 142 Total Number of Hemophilia Patients in Rest of Europe: 2012–2017
Table 143 RoE: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 144 RoE: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 145 RoE: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 146 RoE: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 147 RoE: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 148 Asia Pacific: Plasma Fractionation Market, By Country, 2017–2024 (USD Million)
Table 149 Asia Pacific: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 150 Asia Pacific: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 151 Asia Pacific: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 152 Asia Pacific: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 153 Asia Pacific: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 154 China: Key Macroindicators for the Plasma Fractionation Market
Table 155 China: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 156 China: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 157 China: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 158 China: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 159 China: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 160 Mean Per Capita Factor VIII and IX Use in Japan, 2014 vs 2017 (In Iu/Total Population)
Table 161 Patients With Bleeding Disorders in Japan, 2014 vs 2017
Table 162 Japan: Key Macroindicators for the Plasma Fractionation Market
Table 163 Japan: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 164 Japan: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 165 Japan: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 166 Japan: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 167 Japan: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 168 Total Ig (Grams) Used in Australia, 2006–2015
Table 169 Australian Government Funding for the Supply of Blood and Blood Products, 2008–2017 (USD Million)
Table 170 Australia: Blood Sector Overview (2017)
Table 171 Australia: Key Macroindicators for the Plasma Fractionation Market
Table 172 Australia: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 173 Australia: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 174 Australia: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 175 Australia: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 176 Australia: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 177 India: Number of Patients With Bleeding Disorders, 2012–2016
Table 178 India: Key Macroindicators for the Plasma Fractionation Market
Table 179 India: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 180 India: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 181 India: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 182 India: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 183 India: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 184 Vietnam: Key Macroindicators for the Plasma Fractionation Market
Table 185 Vietnam: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 186 Vietnam: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 187 Vietnam: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 188 Vietnam: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 189 Vietnam: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 190 Indonesia: Key Macroindicators for the Plasma Fractionation Market
Table 191 Indonesia: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 192 Indonesia: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 193 Indonesia: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 194 Indonesia: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 195 Indonesia: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 196 Malaysia: Number of Patients With Bleeding Disorders, 2012–2017
Table 197 Malaysia: Key Macroindicators for the Plasma Fractionation Market
Table 198 Malaysia: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 199 Malaysia: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 200 Malaysia: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 201 Malaysia: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 202 Malaysia: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 203 Rest of Asia Pacific: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 204 Rest of Asia Pacific: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 205 Rest of Asia Pacific: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 206 Rest of Asia Pacific: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 207 Rest of Asia Pacific: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 208 Brazil: Key Macroindicators for the Plasma Fractionation Market
Table 209 Mexico: Key Macroindicators for the Plasma Fractionation Market
Table 210 Latin America: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 211 Latin America: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 212 Latin America: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 213 Latin America: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 214 Latin America: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 215 Hemophilia Patients in the Middle East and Africa, 2012–2017
Table 216 Per Capita Consumption of Factor IX and VIII (Iu/Total Population) in South Africa, Saudi Arabia, and Iraq, 2012–2017
Table 217 Middle East & Africa: Plasma Fractionation Market, By Country, 2017–2024 (USD Million)
Table 218 Middle East & Africa: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 219 Middle East & Africa: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 220 Middle East & Africa: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 221 Middle East & Africa: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 222 Middle East & Africa: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 223 Turkey: Demographic Indicators
Table 224 Turkey: Reported Cases of Blood Disorders, 2012 vs 2014
Table 225 Turkey: Key Macroindicators for the Plasma Fractionation Market
Table 226 Turkey: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 227 Turkey: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 228 Turkey: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 229 Turkey: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 230 Turkey: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 231 Estimated Incidence and Prevalence of Cid, Scid, and Mhc Ii Deficiency in Children in Saudi Arabia
Table 232 Per Capita Consumption of Intravenous Immunoglobulin (IVIG) and Albumin (2015/2016)
Table 233 Saudi Arabia: Blood Disorder Cases, By Type, 2014 vs 2016
Table 234 Saudi Arabia: Key Macroindicators for the Plasma Fractionation Market
Table 235 Saudi Arabia: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 236 Saudi Arabia: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 237 Saudi Arabia: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 238 Saudi Arabia: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 239 Saudi Arabia: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 240 Egypt: Blood Disorder Cases, By Type, 2014–2017
Table 241 Egypt: Key Macroindicators for the Plasma Fractionation Market
Table 242 Egypt: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 243 Egypt: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 244 Egypt: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 245 Egypt: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 246 Egypt: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 247 UAE: Growth in the Number of Blood Donors
Table 248 UAE: Key Macroindicators for the Plasma Fractionation Market
Table 249 UAE: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 250 UAE: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 251 UAE: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 252 UAE: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 253 UAE: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 254 Hemophilia Patients in the Rest of Middle East and Africa, 2012 vs 2017
Table 255 Per Capita Consumption of Factor IX and VIII in South Africa and Qatar (Iu/Total Population), 2013 vs 2017
Table 256 RoMEA: Plasma Fractionation Market, By Product, 2017–2024 (USD Million)
Table 257 RoMEA: Immunoglobulins Market, By Type, 2017–2024 (USD Million)
Table 258 RoMEA: Coagulation Factor Concentrates Market, By Type, 2017–2024 (USD Million)
Table 259 RoMEA: Plasma Fractionation Market, By Application, 2017–2024 (USD Million)
Table 260 RoMEA: Plasma Fractionation Market, By End User, 2017–2024 (USD Million)
Table 261 Growth Strategy Matrix
Table 262 Product Launches/Approvals, January 2016 to April 2019
Table 263 Expansions, January 2016 to April 2019
Table 264 Acquisitions, January 2016 to April 2019
Table 265 Agreements, Collaborations, Joint Ventures, and Partnerships, January 2016 to April 2019


List of Figures (52 Figures)

Figure 1 Research Design
Figure 2 Supply Side: Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Demand Side: Breakdown of Primary Interviews: By End User, Designation, and Region
Figure 4 Data Triangulation Methodology
Figure 5 Immunoglobulins Segment to Dominate the Plasma Fractionation Market, By Product, From 2019 to 2024
Figure 6 Neurology Segment to Register the Highest Growth During the Forecast Period
Figure 7 Plasma Fractionation Market, By End User, 2019 vs 2024 (USD Million)
Figure 8 Geographic Snapshot: Plasma Fractionation Market in 2018
Figure 9 Growing Use of Immunoglobulins in Various Therapeutic Areas is the Major Factor Driving Market Growth
Figure 10 The US Accounted for the Largest Share of the Plasma Fractionation Market in 2018
Figure 11 Asia Pacific to Register the Highest CAGR During the Forecast Period
Figure 12 Developing Countries to Register Higher Growth During the Forecast Period
Figure 13 Global Percentage of Deaths From Respiratory Diseases, 2008 to 2030
Figure 14 Source Plasma Collection in the US, 2004–2017
Figure 15 Plasma Collection Centers in the US and Europe, 2007–2016
Figure 16 Number of Hemophilia A and Hemophilia B Patients Worldwide, 2012–2017
Figure 17 Increasing Consolidation and Rising Adoption of SCIG are the Leading Industry Trends
Figure 18 Plasma Fractionation Market in China vs US, 2017–2024
Figure 19 Porter’s Five Forces Analysis
Figure 20 Immunoglobulin Segment Will Continue to Dominate the Plasma Fractionation Market From 2019 to 2024
Figure 21 Prevalence of Bleeding Disorders, By Country, 2017
Figure 22 Mean Per Capita Usage of Factor VIII (2016 vs 2017)
Figure 23 Mean Per Capita Usage of Factor IX (2016 vs 2017)
Figure 24 Neurology Segment Will Continue to Dominate the Plasma Fractionation Market From 2019 to 2024
Figure 25 Number of Hemophilia Patients in Major Countries, 2016 vs 2017
Figure 26 Hospitals & Clinics to Register the Highest CAGR During the Forecast Period
Figure 27 North America to Dominate the Market During the Forecast Period
Figure 28 Plasma Fractionation Market: Geographic Growth Opportunities
Figure 29 North America: Plasma Fractionation Market Snapshot
Figure 30 Plasma Collection Volume in the US, 2004–2017
Figure 31 Plasma Collection Centers in the US, 2005–2017
Figure 32 Europe: Plasma Fractionation Market Snapshot
Figure 33 Hemophilia A & B Patients in Germany, 2013–2016
Figure 34 APAC: Plasma Fractionation Market Snapshot
Figure 35 Fresh Blood Expenditure in Australia, 2008–2017 (USD Million)
Figure 36 Mean Per Capita Use of Factor VIII and IX in Vietnam, 2014–2017 (Iu/Population)
Figure 37 Patient Population Suffering From Bleeding Disorders in Vietnam, 2014–2017
Figure 38 Blood Donation in Indonesia, 2011–2015 (Million Units)
Figure 39 Key Strategies Adopted By Players (January 2016 to April 2019)
Figure 40 Plasma Fractionation Market Share Analysis, By Key Player, 2018
Figure 41 Competitive Leadership Mapping
Figure 42 Csl: Company Snapshot (2018)
Figure 43 Grifols: Company Snapshot (2017)
Figure 44 Shire: Company Snapshot (2017)
Figure 45 Octapharma: Company Snapshot (2018)
Figure 46 Kedrion: Company Snapshot (2017)
Figure 47 LFB: Company Snapshot (2016)
Figure 48 Biotest: Company Snapshot (2017)
Figure 49 Sanquin: Company Snapshot (2017)
Figure 50 China Biologic Products: Company Snapshot (2017)
Figure 51 Japan Blood Products Organization: Company Snapshot (2016)
Figure 52 GC Pharma: Company Snapshot (2017)

The study involved four major activities in estimating the current market size for plasma fractionation market. Exhaustive secondary research was done to collect information on the market, peer markets, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation were used to estimate the sizes of segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, trade directories, and databases such as D&B Hoovers and Bloomberg Businessweek were referred to identify and collect information for this study.

Primary Research

The plasma fractionation market comprises several stakeholders such as plasma fractionation companies, plasma collection centers, hospitals, and research labs. Primary sources from the supply side, including CEOs, vice presidents, marketing and sales directors, business development managers of plasma fractionation companies, have been considered. Demand-side primary sources include industry experts such hospital professionals, scientists, professors and academic researchers.

Plasma Fractionation Market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the plasma fractionation market. These methods were also used to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research.
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Data Triangulation

After arriving at the overall market size—using market size estimation processes as explained above—the market was split into several segments and subsegments. In order to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Objectives of the Study

  • To define, describe, and forecast the plasma fractionation market, by product and service, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (drivers, restraints, opportunities, challenges, and industry trends)
  • To strategically analyze various segments and subsegments covered in the study with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities in the plasma fractionation market for stakeholders and provide details of the competitive landscape for key players
  • To profile key players in this market and comprehensively analyze their market shares and core competencies
  • To forecast the market size of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
  • To track and analyze competitive developments such as joint ventures, mergers and acquisitions, product developments, agreements, and partnerships in the plasma fractionation market

Scope of the Report

Report Metric

Details

Market size available for years

2017–2024

Base year considered

2018

Forecast period

2019–2024

Forecast units

Value (USD)

Segments covered

Products, application, end users, and regions

Geographies covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

Companies covered

CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), BPL (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China)

Scope of the Report

The research report categorizes the global plasma fractionation market into the following segments and subsegments:

Global plasma fractionation market, by product

  • Immunoglobulin
    • Intravenous immunoglobulin
    • Subcutaneous immunoglobulin
    • Other immunoglobulins
  • Coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Von willebrand factor (VWF)
    • Prothrombin complex concentrates
    • Fibrinogen concentrates
    • Factor XIII
  • Albumin
  • Protease inhibitors
  • Other plasma products (factor X, fibrin sealants, and cryoprecipitate)

Global plasma fractionation market, by application

  • Neurology
  • Immunology
  • Hematology
  • Critical care
  • Pulmonology
  • Hemato-oncology
  • Rheumatology
  • Other applications (dermatology, nephrology, and treatment of infectious diseases)

Global plasma fractionation market, by end user

  • Hospitals and clinics
  • Clinical research laboratories
  • Academic institutes

Global plasma fractionation market, by region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • France
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Australia
    • India
    • Vietnam
    • Indonesia
    • Malaysia
    • South East Asia
    • Rest of Asia Pacific
  • Latin America
  • Middle East and Africa
    • Turkey
    • Egypt
    • UAE
    • Saudi Arabia
    • Rest of Middle East and Africa

Available customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of each company

Geographic Analysis

  • Further breakdown of the RoE plasma fractionation market into Switzerland, Belgium, the Netherlands, Sweden, and others
  • Further breakdown of the RoAPAC plasma fractionation market into New Zealand, South Korea and others

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)
Report Code
PH 4477
Published ON
Mar, 2019
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Plasma Fractionation Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

...

Digital Virtual Assistant - MarketsandMarkets

Home